NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.

NCT05082428

CompletedN/A

Sponsor: Pfizer

Conditions: Ulcerative Colitis

Countries: Finland

The aim of this study is to describe and evaluate clinical outcomes, treatment lines, and to identify the key characteristics of the patients treated with tofacitinib.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Xeljanz (tofacitinib) usage for ulcerative colitis
* Diagnosis of ulcerative colitis (ICD-10: K51.0, K51.1, K51.2, K51.3, K51.5, K51.8, K51.9) between January 2010 and December 2021 (incident or prevalent).

Exclusion Criteria:

* Age \< 18 years at the start of tofacitinib use
* Use of tofacitinib before reimbursement (1.3.2019)
* \< 8 weeks of treatment with tofacitinib at the start of data mining
* History of panproctocolectomy, IPAA or ileostomy.

Locations (1)

Helsinki, Finland